Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Winer

Showing results (71-80 of 105) with videos related to

Pageof 11
Sort By:
Journal of the National Cancer Institute|June 18, 2010
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancerJudy E Garber, Susan Halabi, Sara M Tolaney, et al.
The New England Journal of Medicine|September 3, 2004
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancerKevin S Hughes, Lauren A Schnaper, Donald Berry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2008
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyEric Winer, Julie Gralow, Lisa Diller, et al.
Leukemia|July 30, 2021
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2Jing Yang, Ellen L Weisberg, Xiaoxi Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physiciansJeanne S Mandelblatt, Vanessa B Sheppard, Arti Hurria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2020
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast CancerAranzazu Fernandez-Martinez, Ian E Krop, David W Hillman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast CancerTiffany A Traina, Kathy Miller, Denise A Yardley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2025
Association of tumor-infiltrating lymphocyte subtypes with clinical characteristics and prognosis in young women with hormone receptor-positive breast cancerMegan E Tesch, Yue Zheng, Yaileen D Guzman-Arocho, et al.
JNCI Cancer Spectrum|February 25, 2020
Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer SurvivorsJeffrey A Meyerhardt, Melinda L Irwin, Lee W Jones, et al.
Breast Cancer Research and Treatment|November 19, 2022
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancerAditya Bardia, Ingrid Mayer, Eric Winer, et al.
Pageof 11

Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
Journal of the National Cancer Institute|June 18, 2010
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancerJudy E Garber, Susan Halabi, Sara M Tolaney, et al.
The New England Journal of Medicine|September 3, 2004
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancerKevin S Hughes, Lauren A Schnaper, Donald Berry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2008
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyEric Winer, Julie Gralow, Lisa Diller, et al.
Leukemia|July 30, 2021
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2Jing Yang, Ellen L Weisberg, Xiaoxi Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physiciansJeanne S Mandelblatt, Vanessa B Sheppard, Arti Hurria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2020
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast CancerAranzazu Fernandez-Martinez, Ian E Krop, David W Hillman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast CancerTiffany A Traina, Kathy Miller, Denise A Yardley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2025
Association of tumor-infiltrating lymphocyte subtypes with clinical characteristics and prognosis in young women with hormone receptor-positive breast cancerMegan E Tesch, Yue Zheng, Yaileen D Guzman-Arocho, et al.
JNCI Cancer Spectrum|February 25, 2020
Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer SurvivorsJeffrey A Meyerhardt, Melinda L Irwin, Lee W Jones, et al.
Breast Cancer Research and Treatment|November 19, 2022
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancerAditya Bardia, Ingrid Mayer, Eric Winer, et al.
Pageof 11